NTLA Intellia Therapeutics Inc.

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its third quarter 2022 financial results and operational highlights in a conference call on November 3, 2022, at 8 a.m. ET.

To join the call:

  • U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
  • Please visit this for a simultaneous live webcast of the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at , beginning on November 3, 2022, at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at . Follow us on Twitter .

Intellia Contacts:

Investors:

Ian Karp

Senior Vice President, Investor Relations and Corporate Communications



Lina Li

Senior Director, Investor Relations and Corporate Communications





EN
27/10/2022

Underlying

NTLAIntellia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intellia Therapeutics Inc.

Wedbush Research
  • Wedbush Research
KMX CARMAX INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
MNKD MANNKIND CORP.
SKY SKYLINE CHAMPION CORPORATION
NTLA INTELLIA THERAPEUTICS INC.
CVCO CAVCO INDUSTRIES INC.
ARGX ARGENX ADS
REPL REPLIMUNE GROUP
EMBRAC B EMBRACER GROUP AB
BCAX BICARA THERAPEUTICS INC.
05/19/25 May 19, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
NTLA INTELLIA THERAPEUTICS INC.
05/19/25 May 19, 2025 1 EN
 PRESS RELEASE
Free
NTLA Intellia Therap...

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase...

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were previously progressing on patisiranContinue to observe generally favorable safety and tolerability data in the f...

May 18, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
NTLA INTELLIA THERAPEUTICS INC.
05/08/25 May 8, 2025 1 EN
 PRESS RELEASE
Free
NTLA Intellia Therap...

Intellia Therapeutics Announces First Quarter 2025 Financial Results a...

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phas...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch